Abstract
Background
Erectile dysfunction is related to penile arterial endothelial nitric oxide production.
Asymmetric dimethylarginine (ADMA) and E-selectin are often considered plasma markers
of endothelial function.
Objective
This study investigated the relationship between these plasma markers and cardiovascular
risk factors in patients with erectile dysfunction.
Methods and results
Cardiovascular risk factors, ADMA and E-selectin were assessed in 45 patients with
erectile dysfunction. Plasma markers showed associations with baseline risk factors.
E-selectin levels showed an inverse relationship with age (p = 0.005) and statin therapy (p = 0.03) and a weak association with concomitant β-blocker therapy (p = 0.05). Compared to these relatively weak associations with cardiovascular risk factors,
ADMA levels showed strong associations with pulse pressure (p < 0.001), lack of smoking (p = 0.002) and lipoprotein (a) (p = 0.004) concentrations and weak associations with LDL-cholesterol (p = 0.02), and C-reactive protein levels (p = 0.04). ADMA levels correlated with E-selectin (partial r = 0.76; p < 0.001) after adjustment for lipoprotein (a), pulse pressure and smoking. No change
in E-selectin or ADMA levels was seen after 70 days therapy with sildenafil and no
relationship was found between either plasma marker and the acute pulse wave response
to a single challenge dose of sildenafil.
Conclusion
ADMA levels correlate at baseline with some cardiovascular risk factors including
inflammatory markers and lipoprotein (a) in patients with erectile dysfunction.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Erectile dysfunction and the cardiovascular patient endothelial dysfunction is the common denominator.Heart. 2003; 89: 251-253
- Erectile dysfunction: cardiovascular risk and the role of the cardiologist.Int J Clin Pract. 2003; 57: 96-99
- Relation of erectile dysfunction to angiographic coronary artery disease.Am J Cardiol. 2003; 91: 230-231
- Cardiovascular risk factors and endothelial dysfunction.Clin Sci (London). 2004; 107: 609-615
- The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.Cardiovasc Res. 2003; 59: 824-833
- Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine.Lancet. 2001; 358: 2127-2128
- Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.Arterioscler Thromb Vasc Biol. 2004; 24: 1023-1030
- ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?.Nephrol Dial Transplant. 2001; 16: 1742-1745
- Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data.Dtsch Med Wochenschr. 2004; 129: 820-824
- Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency.Eur J Med Res. 2003; 8: 283-291
- Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention..Eur Heart J. 2003; 24: 1912-1919
- The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function.Vasc Med. 2002; 7: 213-225
- The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.Urology. 1997; 49: 822-830
- Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus.J Am Coll Cardiol. 1999; 34: 2007-2014
- Noninvasive assessment of the digital volume pulse Comparison with the peripheral pressure pulse.Hypertension. 2000; 36: 952-956
- Determination of age-related increases in large artery stiffness by digital pulse contour analysis.Clin Sci (London). 2002; 103: 371-377
- The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function.Vasc Med. 2002; 7: 213-225
- Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage.J Urol. 2004; 171: 1601-1604
- ADMA and oxidative stress.Atheroscler Suppl. 2003; 4: 41-51
- Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype.Biochem Biophys Res Commun. 2003; 308: 984-989
- Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events Does statin treatment influence plasma ADMA levels?.Atheroscler Suppl. 2003; 4: 19-22
- Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors.J Cardiovasc Pharmacol. 2003; 41: 219-222
- Fenofibrate increases the l-arginine:ADMA ratio by increase of l-arginine concentration but has no effect on ADMA concentration.Atherosclerosis. 2004; 173: 239-244
- Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults.Vasc Med. 2003; 8: 185-189
- Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia.J Am Coll Cardiol. 2002; 40: 1241-1247
- Lipid lowering: another method of reducing blood pressure?.J Hum Hypertens. 2002; 16: 753-760
- Endothelium-dependent vasodilation is independent of the plasma l-arginine/ADMA ratio in men with stable angina: lack of effect of oral l-arginine on endothelial function, oxidative stress and exercise performance.J Am Coll Cardiol. 2001; 38: 499-505
- Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?.Diabetologia. 2002; 45: 1609-1616
- Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.Clin Chim Acta. 2003; 336: 1-12
- Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.Semin Thromb Hemost. 2000; 26: 539-545
- Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.Kidney Int. 2002; 62: 339-345
- Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.J Am Soc Nephrol. 2002; 13: 490-496
- Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine.Metabolism. 2004; 53: 1574-1579
- Old and new cardiovascular risk factors: from unresolved issues to new opportunities.Atheroscler Suppl. 2003; 4: 5-17
Article info
Publication history
Published online: July 27, 2005
Accepted:
June 21,
2005
Received in revised form:
June 15,
2005
Received:
January 11,
2005
Identification
Copyright
© 2005 Published by Elsevier Inc.
